Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
42
MXCT Quote, Financials, Valuation and Earnings
Last price:
$1.51
Seasonality move
:
14.91%
Day range:
$1.48 - $1.53
52-week range:
$1.26 - $5.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.63x
P/B ratio:
0.89x
Volume:
1.7M
Avg. volume:
1.3M
1-year change:
-63.77%
Market cap:
$160M
Revenue:
$38.6M
EPS (TTM):
-$0.43
Analysts' Opinion
-
Consensus RatingMaxCyte, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.68, MaxCyte, Inc. has an estimated upside of 345.33% from its current price of $1.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $1.50.
Fair Value
-
According to the consensus of 7 analysts, MaxCyte, Inc. has 345.33% upside to fair value with a price target of $6.68 per share.
MXCT vs. S&P 500
-
Over the past 5 trading days, MaxCyte, Inc. has underperformed the S&P 500 by -1.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MaxCyte, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MaxCyte, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter MaxCyte, Inc. reported revenues of $6.8M.
Earnings Growth
-
MaxCyte, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter MaxCyte, Inc. reported earnings per share of -$0.12.
Enterprise value:
72.4M
EV / Invested capital:
--
Price / LTM sales:
4.63x
EV / EBIT:
--
EV / Revenue:
2.10x
PEG ratio (5yr expected):
-0.14x
EV / Free cash flow:
-1.76x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$23.3M
Return On Assets:
-19.82%
Net Income Margin (TTM):
-132.58%
Return On Equity:
-23.05%
Return On Invested Capital:
-21.09%
Operating Margin:
-164.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $38M | $45.6M | $34.4M | $8.2M | $6.8M | |
| Gross Profit | $29.5M | $35M | $23.3M | $5.2M | $4.2M | |
| Operating Income | -$46.9M | -$46.3M | -$49.7M | -$14.1M | -$11.2M | |
| EBITDA | -$42.9M | -$42M | -$44.8M | -$13M | -$10M | |
| Diluted EPS | -$0.36 | -$0.34 | -$0.43 | -$0.11 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $269.5M | $252.3M | $214.3M | $172.9M | $124.6M | |
| Total Assets | $277.7M | $286.4M | $266.7M | $248.6M | $213.5M | |
| Current Liabilities | $12.6M | $16.8M | $16.6M | $17.6M | $16.1M | |
| Total Liabilities | $13.6M | $32M | $33.4M | $35.3M | $33.2M | |
| Total Equity | $264.1M | $254.4M | $233.4M | $213.3M | $180.3M | |
| Total Debt | $1.2M | $14.9M | $15.4M | $17.4M | $16.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.8M | -$18.8M | -$39.5M | -$4.4M | -$7.5M | |
| Cash From Investing | $32M | $4.5M | $14.6M | $3.6M | $5.2M | |
| Cash From Financing | $2.9M | $2.1M | $963K | $228K | $14K | |
| Free Cash Flow | -$33.7M | -$21.2M | -$41.2M | -$4.8M | -$7.8M | |
MXCT
Sector
Market Cap
$160M
$27.9M
Price % of 52-Week High
28.85%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-0.53%
-1.49%
1-Year Price Total Return
-63.77%
-16.66%
Beta (5-Year)
0.310
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.52
200-day SMA
Sell
Level
$2.03
Bollinger Bands (100)
Sell
Level
1.4 - 1.72
Chaikin Money Flow
Sell
Level
-9.2M
20-day SMA
Sell
Level
$1.58
Relative Strength Index (RSI14)
Sell
Level
44.93
ADX Line
Sell
Level
16.8
Williams %R
Neutral
Level
-69.2308
50-day SMA
Sell
Level
$1.59
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-13.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9141)
Buy
CA Score
(Annual)
Level (0.3561)
Sell
Beneish M-Score
(Annual)
Level (-1.5162)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.5093)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, MXCT has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MXCT average analyst price target in the past 3 months is $6.68.
-
Where Will MaxCyte, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MaxCyte, Inc. share price will rise to $6.68 per share over the next 12 months.
-
What Do Analysts Say About MaxCyte, Inc.?
Analysts are divided on their view about MaxCyte, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MaxCyte, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is MaxCyte, Inc.'s Price Target?
The price target for MaxCyte, Inc. over the next 1-year time period is forecast to be $6.68 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is MXCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MaxCyte, Inc. is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MXCT?
You can purchase shares of MaxCyte, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MaxCyte, Inc. shares.
-
What Is The MaxCyte, Inc. Share Price Today?
MaxCyte, Inc. was last trading at $1.51 per share. This represents the most recent stock quote for MaxCyte, Inc.. Yesterday, MaxCyte, Inc. closed at $1.50 per share.
-
How To Buy MaxCyte, Inc. Stock Online?
In order to purchase MaxCyte, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MXCT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MXCT
Sector
P/E ratio
--
23.85x
PEG ratio
-0.14x
-0.01x
P/B ratio
0.89x
1.81x
Price / LTM sales
4.63x
1.58x
Growth Metrics
MXCT
Sector
Revenue growth
-16.35%
4.62%
Earnings growth
-5.91%
10.5%
Revenue (5-year growth)
12.31%
6.5%
Earnings forecast
-$0.06
-$0.21
Profitability
MXCT
Sector
Profitability FY 2024
$27.4M
$3.6M
Return on invested capital
-21.09%
-31.87%
Return on assets
-19.82%
-28.18%
Return on equity
-23.05%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
MXCT
Sector
Total cash
$105.7M
$26.4M
Short term investments
$126.6M
$25.7M
Total assets
$239.5M
$76.9M
Long term debt
$16.8M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
